Denali Therapeutics Inc. Watch

from 8-K 15 pages Registration Rights Agreement

from 10-Q 6 pages Denali Therapeutics Inc. Outside Director Compensation Policy Initially Adopted and Approved November 10, 2017; Most Recently Amended and Restated January 31, 2025

from 10-Q 2 pages By Overnight Courier and Email / Schuth@dnli.com Denali Therapeutics, Inc. 151 Oyster Point Boulevard South San Francisco, Ca 94080 Attention: Alex Schuth, Chief Operating Officer By: /S/ Ceri Davies Ceri Davies, Head of Neuroscience Drug Discovery Unit 1

from 10-Q 6 pages Re: Collaboration and License Agreement – Notice and Agreement of Program Termination Pursuant to Section 13.3 Dear Ladies and Gentlemen,

from 10-Q 7 pages A.THIS Letter Shall Be Deemed to Constitute Notice by Biogen of the Exercise of Its Right Under Section 14.2(b)(ii) of the Agreement to Terminate the Option Program Known as the Atv:abeta Program (Hereafter Referred to as the “Atv:abeta Terminated Program”) in Its Entirety in All Regions. the Parties Agree That, Notwithstanding Section 14.2(b)(ii) of the Agreement, the Effective Date of Such Termination Shall Be the Date of This Letter (July 26, 2024), and for the Avoidance of Doubt, the [***] Written Notice Period Set Forth in Section 14.2(b)(ii) of the Agreement Shall Be Waived as to the Termination of the Atv:abeta Program

from 10-K 18 pages Denali Therapeutics Inc. Insider Trading Policy and Guidelines With Respect to Certain Transactions in Securities

from 10-K 5 pages Denali Therapeutics Inc. Compensation Recovery Policy as Adopted on November 13, 2023

from 8-K 19 pages Nominating Agreement

from 8-K 39 pages Denali Therapeutics Inc. Securities Purchase Agreement

from 10-Q 6 pages Amendment to Definitive Lrrk2 Agreement and Waiver of and Amendment to Right of First Negotiation, Option, and License Agreement

from 10-K 3 pages Amendment No. 9 to the Development and Manufacturing Services Agreement Dated 6th September 2017 Between Lonza Sales AG and Lonza AG and Denali Therapeutics Inc

from 10-K 7 pages Amendment No. 8 to the Agreement Dated 6th September 2017 Between Lonza Sales AG and Lonza AG and Denali Therapeutics Inc. With Respect To: Quality Agreement

from 10-K 3 pages Amendment No. 7 to the Development and Manufacturing Services Agreement Dated 6th September 2017 Between Lonza Sales AG and Lonza AG and Denali Therapeutics Inc

from 10-K 6 pages Denali Therapeutics Inc. Outside Director Compensation Policy Initially Adopted and Approved November 10, 2017; Most Recently Amended and Restated February 3, 2022

from 10-Q 5 pages From: Denali Therapeutics Inc. 161 Oyster Point Blvd. South San Francisco Ca 94080 U.S.A. Bbb Holding Ltd Hill House 1 Little New Street London, United Kingdom Ec4a 3tr To: F-Star Biotechnology Limited Eddeva B920 Babraham Research Campus Cambridge, United Kingdom Cb22 3at Attn: Chief Executive Officer F-Star Biotechnologische Forschungs- Und ENTWICKLUNGSGES.M.B.H. C/O - F-Star Biotechnology Limited Eddeva B920 Babraham Research Campus Cambridge, United Kingdom Cb22 3at Attn: Chief Executive Officer F-Star Therapeutics Limited Eddeva B920 Babraham Research Campus Cambridge, United Kingdom Cb22 3at Attn: Chief Executive Officer CC: Alliances@f-Star.com June 30th, 2021 Re: Side Letter to License and Collaboration Agreement, the Amended and Restated Gamma License Agreement, the Support Services Agreement and the Share Purchase Agreement [***] Certain Information in This Document Has Been Omitted From This Exhibit Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. 1

from 10-Q 6 pages Denali Therapeutics Inc. Outside Director Compensation Policy Initially Adopted and Approved November 10, 2017; Most Recently Amended and Restated April 16, 2021

from 10-K 7 pages Amendment No. 6 to the Development and Manufacturing Services Agreement Dated 6th September 2017 Between Lonza Sales AG and Denali Therapeutics Lnc

from 10-K 2 pages Amendment Num, 3 to the Development and Manufacturing Services Agreement of 6 September 2017

from 10-K 2 pages Amendment No. 5 to the Development and Manufacturing Services Agreement Dated 6th September 2017 Between Lonza Sales AG and Denali Therapeutics Inc

from 10-K 5 pages Denali Therapeutics Inc. Outside Director Compensation Policy Initially Adopted and Approved November 10, 2017; Most Recently Amended and Restated February 5, 2021